Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Merger or Acquisition (August 2026)
11 slides from Supernus Pharmaceuticals's merger presentation, Aug 3, 2026
Slide 1: Employee Meeting August 3, 2026
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL Employee Meeting August 3, 2026 | 1:00pm ET INTERNAL USE ONLY – Not for external distribution The contents of this deck are contingent on HSR filing, deal signing and in reference to a post - close organizational structure 1 Fil
Slide 2: Antitrust Pledge
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL CONFIDENTIAL Antitrust Pledge: ANTITRUST PLEDGE: Meeting participants shall not engage in any discussion, activity or conduct that may infringe any applicable antitrust, competition, or fair trade law. For example, during the me
Slide 3: Create a diversified CNS biopharmaceutical leader
Create a diversified CNS biopharmaceutical leader 1 Generate significant value for shareholders of both companies 2 Drive significant, durable growth across our diversified portfolio of medicines 3 Enable financial flexibility to pursue growth initiatives to potentially accelerate value creation for
Slide 4: Combination Creates CNS Leader with a ~$2.2Bn Diversified Portfolio of Commercial Assets
Combination Creates CNS Leader with a ~$2.2Bn⁽¹⁾ Diversified Portfolio of Commercial Assets* G ADDICTION / USE DISORDERS PSYCHIATRY NEUROLOGY COMBINED COMPANY NET REVENUE LTM as of 6/30/26 $2,162 million INDIVIOR Total Sublocade $956 Suboxone Film (US) $227 Ex - US Suboxone Tablets and Film $119 Oth
Slide 5: SUBLOCADE for Opioid Use Disorder
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL SUBLOCADE for Opioid Use Disorder 5 7.8m 1 Misuse opioids in U.S. (Total Addressable Market) 4.8m 1 OUD diagnosed in U.S. (Service Addressable Market) 2.0m 2 Received Buprenorphine Medication Assisted Treatment (BMAT) 1. Substan
Slide 6: Ideal Time to Build on Supernus and Indivior Strategic Progress
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL Ideal Time to Build on Supernus and Indivior Strategic Progress* Supernus Indivior STRATEGIC FOCUS • Expanding portfolio through growth of current commercial portfolio, business development, and advancement of mid - to late - st
Slide 7: What does this mean for Supernus employees?
What does this mean for Supernus employees? 7 © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL
Slide 8: Supernus Employee Guidance
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL Supernus Employee Guidance Business as usual! Your current role and responsibilities remain the same, unless otherwise communicated by your manager There are no planned changes to employment status for current Supernus employees
Slide 9: Leadership will keep you informed of key milestones until deal closing
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL Leadership will keep you informed of key milestones until deal closing sometime in Q4 9 Thank you to everyone that supported diligence on this deal and all our employees for your continued work and dedication!
Slide 10: Forward Looking Statements
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL Forward Looking Statements This presentation, and any related oral statements made by representatives of Supernus or Indivior in connection with it, contain forward - looking statements within the meaning of the Private Securiti
Slide 11: Additional Information
© 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. CONFIDENTIAL Additional Information NO OFFER OR SOLICITATION This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offe r t o buy or exchange any securities, or a solicitatio
Supernus Pharmaceuticals — Merger or Acquisition (August 2026) on 6ix